GERD

Gastrointestinal Therapeutics and Diagnostics Technologies and Global Markets Report 2024-2028: Growing Trend toward Screening and Preventive Care and Adoption and Approval of Biological Drugs - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Aprile 5, 2024
Biotechnology, Pharmaceutical, Health, Medical Devices, Sanofi, Growth, Prevalence, AbbVie, Environment, Laxative, Incidence, Antacid, ESG, Gastroesophageal reflux disease, Malignancy, Constipation, Diarrhea, GI, GERD, Irritable bowel syndrome, Prescription, Inflammatory Bowel Diseases, Gastrointestinal disease, OTC, Therapy, Pancreatitis, IBS, Endoscopy, USD, PPI

The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gastrointestinal Therapeutics and Diagnostics Market was valued at USD 86 Billion in 2023, and is expected to reach USD 122.5 Billion by 2028, rising at a CAGR of 7.30%.
  • This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants.
  • This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028.

Stubborn Digestion Issues? PLAMECA Can Help

Retrieved on: 
Mercoledì, Marzo 27, 2024
Diagnosis, Ginger, Esophagus, Gastrointestinal tract, Extrapyramidal system, GERD, Gallbladder, Cancer, Irritable bowel syndrome, Crohn's disease, Quality of life, Great Way Government, Hiatal hernia, Pancreas, IBS, Lactose intolerance, Stomach, Liver, Digestion, Animal feed

FORT LAUDERDALE, Fla., March 27, 2024 /PRNewswire/ -- There are many kinds of digestional disorders. Some are severe, while others are minor (yet uncomfortable) inconveniences. For those managing ongoing digestional discomfort, PLAMECA's Digestissimoh! offers clean, safe, and effective relief.

Key Points: 
  • Is a Great Way to Lighten Digestion Across the Board
    FORT LAUDERDALE, Fla., March 27, 2024 /PRNewswire/ -- There are many kinds of digestional disorders.
  • supplement is a perfect example of a safe, natural, and effective way to manage stubborn digestive issues over time," Fernández explains.
  • uses natural ingredients such as ginger, digestive enzymes, and marine coral to lighten digestion.
  • offers a safe, effective, natural way to lighten their digestion and keep things functioning on a day-to-day basis.

Implantica completes Human Factors Validation Study for RefluxStop™ as part of the US FDA Premarket Approval Process

Retrieved on: 
Martedì, Marzo 26, 2024
Cancer, PPI, PMID, Gastroesophageal reflux disease, Patient, Internet, Foregut, GERD, Northwestern University, Surgeon, Certification, PMA, Literature, Human factors and ergonomics, FDA, Pharmaceutical industry

), a medtech company at the forefront of bringing advanced technology into the body, announces completion of the Human Factors Validation Study with 16 US surgeons as part of the US FDA Premarket Approval (PMA) process for RefluxStop™.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces completion of the Human Factors Validation Study with 16 US surgeons as part of the US FDA Premarket Approval (PMA) process for RefluxStop™.
  • In March, 16 foregut surgeons in the United States (U.S.) participated in a Human Factors Validation Study of the RefluxStop™ procedure at Northwestern University's Simulation Lab in Chicago.
  • In the next step of the study, an independent third party is evaluating the data collected during testing in Chicago.
  • Dr. Peter Forsell, CEO of Implantica, says, "We're very grateful to the independent US surgeons and healthcare professionals who participated in the Human Factors Validation study, a key milestone for the FDA approval process.

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Retrieved on: 
Mercoledì, Marzo 20, 2024
Lucid, Washington Convention Center, Walter, GERD, Esophagus, Cancer, Abstract, DDW, Barrett's esophagus, Assessment, Annual general meeting

NEW YORK, March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that four abstracts related to its groundbreaking technologies, including its EsoGuard® Esophageal DNA Test, have been accepted for presentation by it and its collaborators at this year's Digestive Disease Week (DDW) Annual Meeting 2024—the world's premier meeting for digestive disease professionals.

Key Points: 
  • NEW YORK, March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that four abstracts related to its groundbreaking technologies, including its EsoGuard® Esophageal DNA Test, have been accepted for presentation by it and its collaborators at this year's Digestive Disease Week (DDW) Annual Meeting 2024 —the world's premier meeting for digestive disease professionals.
  • "We are excited that our technologies will be prominently featured in multiple presentations at this year's DDW conference," said Suman Verma, M.D., Ph.D., Lucid Senior Vice President, and Chief Scientific Officer.
  • DDW 2024 will be held at the Walter E. Washington Convention Center in Washington, D.C., May 18 to 24, 2024.
  • Details on the time and location of the presentations will be provided prior to the conference.

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Marzo 7, 2024
Esophagus, Hercules, Pharmacy, Quarter, Research, Heartburn, DUAL, Regulation, Forecasting, FDA, Pain, Table, PDUFA, Vomiting, Inflammation, GERD, Ratio, PPI, GAAP, Business, Webcast, Enzyme inhibitor, Patient, Express Scripts, Helicobacter pylori, Clinical trial, Vonoprazan/amoxicillin, PBM, G&A, Eosinophilic esophagitis, Tablet, NDA, Prescription, Vonoprazan/amoxicillin/clarithromycin, Pharmaceutical industry

Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.

Key Points: 
  • Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.
  • Fourth quarter 2023 net loss included a non-cash charge related to stock-based compensation of $24.6 million compared to $6.7 million for fourth quarter 2022.
  • Phathom will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results and business highlights today, March 7, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

On Feb 6th, Penn Medicine Becker ENT & Allergy Opens a New Location to Increase Access to Quality Care in Woodbury, NJ

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Allergy, Polyp (medicine), Steam, MD, Immunotherapy, Physician, Quality of life, Medicine, GERD, Probiotic, Ear, Honey, Health, Thyroid disease, ENT, Health care, Instrument, Patient, Disorder, Allergen, Becker, Nose, Veterinary medicine

WOODBURY, N.J., Feb. 28, 2024 /PRNewswire-PRWeb/ -- Expanding Patient Care: Penn Medicine Becker ENT & Allergy's New Woodbury Facility

Key Points: 
  • WOODBURY, N.J., Feb. 28, 2024 /PRNewswire-PRWeb/ -- Expanding Patient Care: Penn Medicine Becker ENT & Allergy's New Woodbury Facility
    The new Penn Medicine Becker ENT & Allergy location in Woodbury is part of their ongoing mission to deliver comprehensive care for ear, nose, throat, and allergy issues to more patients.
  • What the New Penn Medicine Becker ENT & Allergy Location Means for Woodbury, NJ
    The opening of the new Becker ENT location in Woodbury is a major boon for the local community.
  • Penn Medicine Becker ENT & Allergy offers a vast array of ENT and allergy services .
  • Contacting Penn Medicine Becker ENT & Allergy for Care in Woodbury, NJ
    To experience the quality and personalized care that Penn Medicine Becker ENT & Allergy offers, residents of Woodbury, NJ, and surrounding areas can schedule an appointment.

How Healthcare2U Can Help California Businesses Provide Affordable Employee Healthcare Amid Minimum Wage Hikes

Retrieved on: 
Giovedì, Febbraio 22, 2024
Diabetes, Physician, Growth, Foodservice, GERD, DPC, Heart failure, Health, Fear, Health equity, Health insurance

-Andy Bonner, Healthcare2U

Key Points: 
  • -Andy Bonner, Healthcare2U
    President and CEO of Healthcare2U, Andy Bonner, is excited to be expanding its healthcare services in the California market.
  • In January this year, California passed a law that raised the minimum wage requirement for exempt employees to $16, with food services and healthcare employees receiving an increase of $18 to $23.
  • However, with the rise of inflation and minimum wage requirements, employer's access to affordable health plans may affect the benefits they provide.
  • The company ensures to address the evolving landscape of healthcare, offering alternatives to ensure accessibility, affordability, and quality in healthcare services.

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Retrieved on: 
Martedì, Febbraio 13, 2024
Urinary tract infection, Gastroesophageal reflux disease, Research, Heartburn, Toxicity, Magnesium, Polyp, Liver, CYP, CGA, Achlorhydria, Esophagitis, Patient, PBM, Vitamin B12, Vonoprazan, Kidney, Spine, Lactation, Absorption, Hypokalemia, SCAR, Calcium, Express Scripts, TIN, Endoscopy, Tablet, Express, Magnesium deficiency, Hypocalcemia, Diarrhea, Hypersensitivity, Physician, Gastritis, Malabsorption, GERD, PPI, Hypertension, SJS, Enzyme inhibitor, EGFR, Stevens–Johnson syndrome, Indigestion, Nelfinavir, Clostridioides, Abdominal pain, Hip, Pharmacy, Enzyme, Glomus tumor, FDA, CDAD, Atazanavir, Risk, BMJ Open, Wrist, Drug, Impairment, Pharmaceutical industry

Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.

Key Points: 
  • Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.
  • doi:10.1136/ bmjgast-2022-000941
    VOQUEZNA® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated:
    for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD in adults.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.
  • Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR

Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories

Retrieved on: 
Mercoledì, Febbraio 7, 2024
Partnership, Collaboration, Regurgitation, GI, IND, Patient, Gastroparesis, FDA, Food, D2, PPI, Gastroesophageal reflux disease, FACC, Disease, Heartburn, GERD, Pharmaceutical industry

Falk Pharma”), has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD) as the second indication in their licensed territories.

Key Points: 
  • Falk Pharma”), has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD) as the second indication in their licensed territories.
  • In October 2021, Renexxion and Dr. Falk Pharma announced an exclusive Licensing and Collaboration Agreement to advance naronapride initially for gastroparesis in Greater Europe (including UK), Russia, Central Asian Republics, and certain Australasian countries.
  • Today, Renexxion is pleased to confirm that Dr. Falk Pharma will also advance naronapride for PPI-non-responsive symptomatic GERD in these regions.
  • This is a welcomed addition to our pipeline which includes naronapride for gastroparesis.”
    “We are very pleased that our European partner, Dr. Falk Pharma, chose PPI-nrsGERD as its next indication for development for naronapride in their territories.

Implantica's RefluxStop™ procedure now available in Norway

Retrieved on: 
Martedì, Gennaio 30, 2024
Akershus University Hospital, Patient, Certification, GERD, Medical device

), a medtech company at the forefront of bringing advanced technology into the body, announces that the RefluxStop™ procedure is now available at the Akershus University Hospital in Norway.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces that the RefluxStop™ procedure is now available at the Akershus University Hospital in Norway.
  • Earlier this month, the RefluxStop™ procedure, a new cutting-edge surgical treatment for GERD, was performed on five patients by Dr. Robin Gaupset and Dr. Lars Eftang at Akershus University Hospital in Oslo.
  • Dr. Gaupset says, "We believe RefluxStop™ has the potential to offer a superior surgical treatment against GERD/reflux, with fewer side effects compared to current alternatives.
  • According to Dr. Eftang, "RefluxStop could make a surgical treatment for GERD available to patients not previously considered for surgery.